Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review
Top Cited Papers
Open Access
- 25 June 2023
- journal article
- review article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 161, 39-45
Abstract
No abstract availableKeywords
Funding Information
- Health Technology Assessment Programme (NIHR128862)
- National Institute for Health and Care Research
This publication has 10 references indexed in Scilit:
- Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological studyJournal of Clinical Epidemiology, 2022
- Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instructionJournal of Clinical Epidemiology, 2022
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Community-based complex interventions to sustain independence in older people, stratified by frailty: a protocol for a systematic review and network meta-analysisBMJ Open, 2021
- The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its applicationJournal of Clinical Epidemiology, 2020
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or bothBMJ, 2017
- Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviewsSystematic Reviews, 2016
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)Journal of Clinical Epidemiology, 2011